75738-58-8

• 常用中文名：盐酸头孢甲肟
• 常用英文名：Cefmenoxime Hydrochloride
• CAS号：75738-58-8
• 分子式：C₃₂H₃₅ClN₁₈O₁₀S₆
• 分子量：1059.6
• 相关类别： 原料药 抗生素类药物 头孢菌素类药
• 发布时间：2018-06-05 08:00:00
• 更新时间：2026-06-30 09:30:22
• 盐酸头孢甲肟(Cefmenoxime Hcl)是第三代头孢类抗生素。

名称

• 中文名: 盐酸头孢甲肟
• 英文名: cefmenoxime hydrochloride
• 中文别名: (6R,7R)-7-[2-(2-氨基-4-噻唑基)(甲氧亚氨基)乙酰氨基]-3-[[(1-甲基-1H-四唑-5-基)-硫]甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸盐酸盐; 半盐酸头孢甲肟; 盐酸头孢甲肟 标准品; 盐酸甲肟; 盐酸氨噻唑肟; CEFMENOXIME头孢甲肟; 头孢甲肟系列/盐酸头孢甲肟; 盐酸头孢甲肟,10 MM DMSO 溶液; 盐酸盐头孢甲肟; 头孢甲肟盐酸盐; (6R,7R)-7-((Z)-2-(2-氨基噻唑-4-基)-2-(甲氧基亚氨基)乙酰胺基)-3-(((1-甲基-1H-四唑-5-基)硫基)甲基)-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸盐酸盐(2:1); (6R,7R)-7-[2Z-(2-氨基-4-噻唑基)(甲氧亚氨基)乙酰氨基]-3-[[(1-甲基-1H-四唑-5-基)-硫]甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸盐酸盐(2:1); (6R,7R)-7-(2-(2-氨基-4-噻唑基)(甲氧亚氨基)乙酰氨基)-3-(((1-甲基-1H-四唑-5-基)-硫)甲基)-8-氧代-5-硫杂-1-氮杂双环(4.2.0)辛-2-烯-2-甲酸盐酸盐; 盐酸氨噻肟唑头孢菌素
• 英文别名: SCE 1365 hydrochloride; Cemix; Cefotetan (500 mg); CefMenoxiMe SodiuM; Cefmenoxime (hydrochloride); Cefmenoxime HCL Powder Standd; Cefmenoxime hydrochloride //BP; ab50912hemihydrochloride; Apacef; SCE-1365(free acid); Cefmax; Bestcall; (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid hydrochloride(2:1); 7-[[2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid hydrochloride; cefmenoximehemihydrochloride; sce1365hydrochloride; 7beta-[2-(2-Aminothiazol-4-yl)-(Z)-2-(methoxyiminoacetamido)]-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]ch-3-em-4-cboxylic acid hemihydrochloride; Tacef; 8-[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino-4-[(1-methyltetrazol-5-yl)sulfanylmethyl]-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-cboxylic acid hydrochloride (2:1); 2Cefmenoxime·Hydrochloride; Abbott 50192 (HCl); CEFOTETAN SODIUM; Apatef; (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(MethoxyiMino)acetyl]amino]-3-[[(1-Methyl-1H-tetrazol-5-yl)thio]Methyl]-8-oxo-5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic Acid HeMihydrochloride; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, hydrochloride (2:1), (6R,7R); 7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid hemihydrochloride; )(methoxyimino)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-ox; CefMenoxiMe HCL Sterile; Yamatetan; (6R)-7α-[[(2-Amino-4-thiazolyl)[(Z)-methoxyimino]acetyl]amino]-3-[[(1-methyl-1H-tetrazole-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-cboxylic acid·0.5hydrochloride; CEFMENOXIME HEMIHYDROCHLORIDE;SCE-1365 HEMIHYDROCHLORIDE; Cepan Darvilen; Abbott; Bestron; hydrochloride(2:1),(6r-(6-alpha,7-beta(z)))-o; Hydrochloride (syn-isomer); Cefmenoxime HCl (SCE-1365); Cefmenoxime hydrochloride, 10 mM in DMSO; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)-1-oxoethyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-, hydrochloride (1:1); (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrochloride (1:1); CEFOTETAN; Cefotetan acid; SCE-1365 hemihydrochloride; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, hydrochloride (2:1), [6R-[6α,7β(Z)]]; Cefmenoxime hydrochloride; Ceftenon; CEFMENOXIME HCL; CEFMENOXIME HYDROCHLORIDE

物化性质

• 分子式: C₃₂H₃₅ClN₁₈O₁₀S₆
• 分子量: 1059.6
• 精确质量: 1058.0796341
• PSA: 269.65000
• LogP: 0.04020
• 外观性状: 白色至类白色固体
• 储存条件: 库房低温通风干燥

生物活性

• 描述: 盐酸头孢甲肟(Cefmenoxime Hcl)是第三代头孢类抗生素。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染
• 参考文献:

  [1]. Yokota N, et al. Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis. Jpn J Antibiot. 1995 May;48(5):602-9.

  [2]. Paladino JA, et al. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9.

  [3]. Duncker GI, et al. Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XI0367700 CAS REGISTRY NUMBER : 75738-58-8 LAST UPDATED : 199612 DATA ITEMS CITED : 8 MOLECULAR FORMULA : C16-H17-N9-O5-S3.1/2Cl-H MOLECULAR WEIGHT : 529.77 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >20 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 14,297,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 13150 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,2615,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2680 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,2615,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 17540 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 14,297,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 11830 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968- Volume(issue)/page/year: 35,2615,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 7830 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 22,1605,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10500 mg/kg/35D-I TOXIC EFFECTS : Gastrointestinal - other changes REFERENCE : TAKHAA Takeda Kenkyusho Ho. Journal of the Takeda Research Laboratories. (Takeda Yakuhin Kogyo K.K., 2-17-85 Jusohon-machi, Yodogawa-ku, Osaka 532, Japan) V.29- 1970- Volume(issue)/page/year: 42,104,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 8400 mg/kg/4W-I TOXIC EFFECTS : Liver - changes in liver weight Endocrine - changes in thymus weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - true cholinesterase REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 16,2421,1988

安全

• 海关编码: 3003209000

海关

海关编码	3003209000